SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for BIOLASE, INC (BIOL) (CIK 0000811240) — May 24, 2005

BIOLASE, INC (BIOL) (CIK 0000811240)
Date: May 24, 2005 · CIK: 0000811240 · Accession: 0000000000-05-025698

AI Filing Summary & Sentiment

Date
May 24, 2005
Author
Jeanne Bennett
Form
UPLOAD
Company
BIOLASE, INC (BIOL) (CIK 0000811240)

Letter

Mail Stop 0306 John W. Hohener, Executive Vice President and Chief Financial Officer Biolase Technology Inc. 981 Calle Amanecer San Clemente, California 92673 Via U S Mail and FAX [ (949) 361-0204 ]

Re: Biolase Technology Inc. Form 8-K for Item 4.02 Filed May 20, 2005 File No. 0-19627

Dear Mr. Hohener:

We have reviewed your filing and have the following comment. Where indicated, we think you should revise your document in response to this comment. If you disagree, we will consider your explanation as to why our comment is inapplicable or a revision is unnecessary. After reviewing this information, we may or may not raise additional comments.

Please understand that the purpose of our review process is to assist you in your compliance with the applicable disclosure requirements and to enhance the overall disclosure in your filing. We look forward to working with you in these respects. We welcome any questions you may have about our comments or any other aspect of our review. Feel free to call the applicable staff person at the telephone number listed at the end of this letter.

Form 8-K Filed May 20, 2005

1. We note that you intend to file restated financial statements. However you have not indicated how or when you intend to do so. Please state how and when you intend to file restated financial statements. We may have further comment after you file the restated financial statements.

Mr. John W. Hohener Biolase Technology Inc. May 24, 2005 Page 2

* * * * *

Please file your supplemental response and amendment via EDGAR in response to this comment within 5 business days after the date of this letter. Please contact the staff immediately if you require longer than 5 business days to respond.

We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing reviewed by the staff to be certain that they have provided all information investors require for an informed decision. Since the registrant and its management are in possession of all facts relating to a registrant`s disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made.

In connection with responding to our comments, please provide, in writing, a statement from the registrant acknowledging that: * the registrant is responsible for the adequacy and accuracy of the disclosure in the filing; * staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and * the registrant may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

In addition, please be advised that the Division of Enforcement has access to all information you provide to the staff of the Division of Corporation Finance in our review of your filing or in response to our comments on your filing.

If you have any questions, please call me at (202) 551-3606. In my absence, you may call Brian Cascio, Branch Chief at (202) 551- 3676.

Sincerely,
Jeanne Bennett
Staff Accountant

Show Raw Text
<DOCUMENT>
<TYPE>LETTER
<SEQUENCE>1
<FILENAME>filename1.txt
<TEXT>

May 24, 2005

Mail Stop  0306

John W. Hohener, Executive Vice President and Chief Financial
Officer
Biolase Technology Inc.
981 Calle Amanecer
San Clemente, California 92673

Via U S Mail and FAX [ (949) 361-0204 ]

Re:	Biolase Technology Inc.
	Form 8-K for Item 4.02
	Filed  May 20, 2005
	File No. 0-19627

Dear  Mr. Hohener:

	We have reviewed your filing and have the following comment.
Where indicated, we think you should revise your document in
response
to this comment.  If you disagree, we will consider your
explanation
as to why our comment is inapplicable or a revision is
unnecessary.
After reviewing this information, we may or may not raise
additional
comments.

	Please understand that the purpose of our review process is
to
assist you in your compliance with the applicable disclosure
requirements and to enhance the overall disclosure in your filing.
We look forward to working with you in these respects.  We welcome
any questions you may have about our comments or any other aspect
of
our review.  Feel free to call the applicable staff person at the
telephone number listed at the end of this letter.

Form 8-K Filed May 20, 2005

1. We note that you intend to file restated financial statements.
However you have not indicated how or when you intend to do so.
Please state how and when you intend to file restated financial
statements. We may have further comment after you file the
restated
financial statements.

Mr. John W. Hohener
Biolase Technology Inc.
May 24, 2005
Page 2

*   *   *   *   *

	Please file your supplemental response and amendment via
EDGAR
in response to this comment within 5 business days after the date
of
this letter.  Please contact the staff immediately if you require
longer than 5 business days to respond.

      We urge all persons who are responsible for the accuracy and
adequacy of the disclosure in the filing reviewed by the staff to
be
certain that they have provided all information investors require
for
an informed decision.  Since the registrant and its management are
in
possession of all facts relating to a registrant`s disclosure,
they
are responsible for the accuracy and adequacy of the disclosures
they
have made.

      In connection with responding to our comments, please
provide,
in writing, a statement from the registrant acknowledging that:
* the registrant is responsible for the adequacy and accuracy of
the
disclosure in the filing;
* staff comments or changes to disclosure in response to staff
comments do not foreclose the Commission from taking any action
with
respect to the filing; and
* the registrant may not assert staff comments as a defense in any
proceeding initiated by the Commission or any person under the
federal securities laws of the United States.

In addition, please be advised that the Division of Enforcement
has
access to all information you provide to the staff of the Division
of
Corporation Finance in our review of your filing or in response to
our comments on your filing.

	If you have any questions, please call me at (202) 551-3606.
In
my absence, you  may call Brian Cascio, Branch Chief at (202) 551-
3676.

							Sincerely,

							Jeanne Bennett
							Staff Accountant

</TEXT>
</DOCUMENT>